Stockreport

Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility [Seeking Alpha]

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF NTLA's CRISPR/Cas9 gene editing offers potentially best-in-class, one-time therapies, but irreversible gene edits raise significant safety risks. The FDA's imminent r [Read more]